Can chronic stress, circadian disruption, and perimenopause reinforce HPA-HPO dysregulation?

The perimenopausal transition represents a critical window of vulnerability where endocrine, circadian, and stress-response pathways intersect to drive systemic dysregulation.

Mechanistic pathways of endocrine desynchronization

• SCN-to-kisspeptin signaling: Circadian disruption impairs suprachiasmatic nucleus (SCN) daily timing signals to kisspeptin and GnRH neurons, directly disrupting LH surge timing and baseline pulsatility.
• Impaired GnRH and LH pulsatility: Ovarian steroid fluctuations during perimenopause weaken normal negative feedback on the HPO axis. Concurrently, chronic stress triggers HPA axis activation (via CRH and cortisol) that directly inhibits GnRH neurons, reducing LH pulse frequency and amplitude.
• GABAergic and stress feedback alterations: Declining progesterone-derived neurosteroids in perimenopause weaken GABAergic inhibition on CRH neurons. This impairs cortisol negative feedback, elevating cortisol levels which in turn suppress reproductive hormone pulsatility.

Sleep and stress feedback dynamics

• Sleep fragmentation and HPA activation: Shifted sleep timing and poor sleep continuity impair HPA-axis regulation, elevating bedtime cortisol levels, blunting the cortisol awakening response, and altering normal sleep-dependent inhibition of LH pulsatility.
• Self-reinforcing feedback loops: These parallel pathways create a bidirectional cycle. Unstable GnRH/LH dynamics and fluctuating ovarian steroids sensitize the HPA axis to stress. Conversely, heightened stress reactivity and elevated cortisol further suppress reproductive pulsatility, reinforcing systemic HPA-HPO desynchronization.

Bottom line

• Bottom line: Chronic stress, circadian-driven sleep disruptions, and the perimenopausal transition engage convergent pathways—specifically SCN-to-kisspeptin dysfunction, weakened GABAergic inhibition, and sleep-induced cortisol elevations—to lock the HPA and HPO axes into a self-reinforcing cycle of endocrine dysregulation.